Chromenone derivatives useful for the treatment of neurodegenerative diseases
申请人:AxoGlia Therapeutics S.A.
公开号:EP2112145A1
公开(公告)日:2009-10-28
Compounds of general formula (I) and (II)
in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.
Muscarinic acetylcholine receptor-active compounds have potential for the treatment of Alzheimer’s disease. In this study, a series of natural and synthetic flavones and flavonols was assayed in vitro for their ability to inhibit radioligand binding at human cloned M1 muscarinic receptors. Several compounds were found to possess competitive binding affinity (Ki = 40–110 µM), comparable to that of acetylcholine (Ki = 59 µM). Despite the fact that these compounds lack a positively-charged ammonium group under physiological conditions, molecular modelling studies suggested that they bind to the orthosteric site of the receptor, mainly through non-polar interactions.
CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
申请人:Coowar Djalil
公开号:US20110144194A1
公开(公告)日:2011-06-16
Compounds of general formula (I) and (II) in which R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, R
10
, R
11
, R
12
, R
13
, R
14
and R
15
have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.